Publications by authors named "N C Gerber"
Background: In patients with breast cancer, prone radiation therapy (RT) has been shown to reduce heart and lung dose. Though prone positioning is routinely used for whole breast RT, its use when treating the regional lymph nodes (RLNs) is not widespread.
Methods: In this phase I-II trial for stage IB-IIA breast cancer treated with lumpectomy or mastectomy, patients received 40.
Purpose: TRK fusions are detected in less than 2% of central nervous system tumors. There are limited data on the clinical course of affected patients.
Experimental Design: We conducted an international retrospective cohort study of patients with TRK fusion-driven CNS tumors.
Importance: The combination of ifosfamide and etoposide (IE) is commonly used to treat relapsed or refractory osteosarcoma; however, second-line treatment recommendations vary across guidelines.
Objective: To evaluate whether the addition of lenvatinib to IE (LEN-IE) improves outcomes in children and young adults with relapsed or refractory osteosarcoma.
Design, Setting, And Participants: The OLIE phase II, open-label, randomized clinical trial was conducted globally across Europe, Asia and the Pacific, and North America.
Article Synopsis
- - The SIOP-CNS-GCT-II European trial studied the effects of age on acute toxicity from chemotherapy in patients with central nervous system germ cell tumors, using various chemotherapy regimens based on tumor type.
- - Analysis included 296 patients across three age groups: children (≤11 years), adolescents (12-17 years), and adults (≥18 years), revealing that adults experienced lower rates of severe adverse events compared to adolescents despite similar chemotherapy dosages.
- - The study concluded that adults can safely tolerate intensive chemotherapy protocols with less toxicity than adolescents, indicating a need for further investigation into how age influences chemotherapy-related toxicity.
Background: Breast-conserving surgery (BCS) followed by adjuvant radiotherapy (RT) is a standard treatment for ductal carcinoma in situ (DCIS). A low-risk patient subset that does not benefit from RT has not yet been clearly identified. The DCISionRT test provides a clinically validated decision score (DS), which is prognostic of 10-year in-breast recurrence rates (invasive and non-invasive) and is also predictive of RT benefit.
View Article and Find Full Text PDF